Advertisement

Topics

TapImmune aims for $70mm PIPE concurrent with closing of merger

15:40 EDT 12 Jun 2018 | Elsevier Business Intelligence

TapImmune Inc. (cancer immunotherapies) priced a private placement of 17.5mm common shares at $4 apiece, for gross proceeds o...

Original Article: TapImmune aims for $70mm PIPE concurrent with closing of merger

NEXT ARTICLE

More From BioPortfolio on "TapImmune aims for $70mm PIPE concurrent with closing of merger"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...